









Markets
/
Stocks
/
nasdaq-dvax
/

Dynavax Technologies Corp

DVAX

10.990USD

+0.690+6.70%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

1.29BMarket Cap

LossP/E TTM



Dynavax Technologies Corp

10.990

+0.690+6.70%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Dynavax Technologies Corp

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dynavax Technologies Corp's Score

Industry at a Glance

Industry Ranking

4 / 407

Overall Ranking

39 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

23.000

Target Price

+123.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dynavax Technologies Corp Highlights

StrengthsRisks

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -30.11, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 114.03M shares, decreasing 19.18% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.10K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 8.73, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.73

Change



Financials

6.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.78

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.95

Key Metrics

Free cash flow

No Data

Dynavax Technologies Corp's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 7.94, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -30.11, which is -667.61% below the recent high of 170.92 and -902.34% above the recent low of -301.83.

Score

Industry at a Glance

Previous score

7.94

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 4/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 7.60, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Dynavax Technologies Corp is 25.00, with a high of 32.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

23.000

Target Price

+123.30%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Dynavax Technologies Corp

DVAX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 9.14, which is higher than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 11.58 and the support level at 10.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.52

Change

0.62

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.087

Buy

RSI(14)

67.410

Neutral

STOCH(KDJ)(9,3,3)

60.689

Buy

ATR(14)

0.308

High Vlolatility

CCI(14)

253.982

Overbought

Williams %R

17.857

Overbought

TRIX(12,20)

0.167

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

10.358

Buy

MA10

10.382

Buy

MA20

10.185

Buy

MA50

10.007

Buy

MA100

10.307

Buy

MA200

11.122

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 97.24%, representing a quarter-over-quarter decrease of 10.62%. The largest institutional shareholder is The Vanguard, holding a total of 8.40M shares, representing 7.17% of shares outstanding, with 3.18% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

15.80M

-15.27%

Deep Track Capital LP

15.73M

-11.61%

The Vanguard Group, Inc.

Star Investors

8.40M

-3.07%

State Street Investment Management (US)

6.40M

-5.81%

Chicago Capital, LLC

5.23M

-2.18%

Two Sigma Investments, LP

3.80M

+67.74%

Dimensional Fund Advisors, L.P.

3.64M

-9.11%

Renaissance Technologies LLC

Star Investors

2.89M

+6.69%

Geode Capital Management, L.L.C.

2.69M

-12.30%

William Blair & Company, L.L.C. (Research)

2.28M

+0.31%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 6.86, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.